Revolade Den europeiske union - norsk - EMA (European Medicines Agency)

revolade

novartis europharm limited - eltrombopag - purpura, trombocytopenisk, idiopatisk - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Sandimmun 50 mg/ ml Norge - norsk - Statens legemiddelverk

sandimmun 50 mg/ ml

novartis norge (2) - ciklosporin - konsentrat til infusjonsvæske, oppløsning - 50 mg/ ml

Berocca Norge - norsk - Statens legemiddelverk

berocca

bayer as - askorbinsyre / monofosfotiamin / riboflavinnatriumfosfathydrat / nikotinamid / kalsiumpantotenat / pyridoksinhydroklorid / cyanokobalamin / folsyre / biotin / kalsiumkarbonat / magnesiumsubkarbonat, tungt / magnesiumsulfatdihydrat / sinksitrattrihydrat - brusetablett - 500 mg / 18.54 mg / 15 mg / 50 mg / 25 mg / 10 mg / 0.01 mg / 0.4 mg / 0.15 mg / 244 mg / 195 mg / 328 mg / 32 mg

Mavenclad Den europeiske union - norsk - EMA (European Medicines Agency)

mavenclad

merck europe b.v. - cladribine - multippel sklerose - immunsuppressive - behandling av voksne pasienter med svært aktiv recidiverende multippel sklerose (ms) som definert av kliniske eller imagingfunksjoner.

Qinlock Den europeiske union - norsk - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Mavenclad 10 mg Norge - norsk - Statens legemiddelverk

mavenclad 10 mg

orifarm as - kladribin - tablett - 10 mg

Olysio Den europeiske union - norsk - EMA (European Medicines Agency)

olysio

janssen-cilag international nv - simeprevir - hepatitt c, kronisk - antivirale midler til systemisk bruk - olysio er angitt i kombinasjon med andre legemidler til behandling av kronisk hepatitt c (chc) hos voksne pasienter. for hepatitt c-virus (hcv) genotypen bestemt aktivitet.

Crestor 10 mg Norge - norsk - Statens legemiddelverk

crestor 10 mg

grünenthal gmbh - rosuvastatinkalsium - tablett, filmdrasjert - 10 mg

Crestor 5 mg Norge - norsk - Statens legemiddelverk

crestor 5 mg

grünenthal gmbh - rosuvastatinkalsium - tablett, filmdrasjert - 5 mg

Crestor 20 mg Norge - norsk - Statens legemiddelverk

crestor 20 mg

grünenthal gmbh - rosuvastatinkalsium - tablett, filmdrasjert - 20 mg